Tesla Inc.’s board of directors is at a critical juncture, wedged between a larger-than-life figure to whom many are personally close and their larger responsibility to shareholders.
Elon Musk’s astonishing interview with the New York Times has heightened concerns surrounding the health of Tesla’s chairman and chief executive officer, with shares plunging 8.9 percent Friday, the largest drop in nearly two years. The references to Ambien use and driving while tweeting are fueling calls for Tesla’s board to step up its oversight of the company’s CEO and largest shareholder.
“If the board is going to take any initiative, they will clamp him